Key Highlights

• Insurance coverage reached over 98% of US lives, and a billing code (J-code) took effect in October 2025, which can ease reimbursement.

• In compassionate use after ruxolitinib failure, 76% of patients were alive at day 100, compared with roughly 20% to 30% survival for other third-line agents cited by the company.

• The shift from US$17.2 million to US$120.3 million of Revenue is a step change, but it is the first full commercial year, so growth rates will normalise.

• For the year ended 30 June 2026, reported on 27 August 2026, the group posted total revenue of US$120.3 million, up from US$17.2 million a year earlier, and a net loss of US$57.5 million, down 44% from US$102.1 million.

What does it take for a cell therapy developer to move from clinical-stage promise to commercial revenue? Mesoblast (ASX:MSB) is now partway through that journey. For the year ended 30 June 2026, reported on 27 August 2026, the group posted total revenue of US$120.3 million, up from US$17.2 million a year earlier, and a net loss of US$57.5 million, down 44% from US$102.1 million. Ryoncil, its approved therapy for children with steroid-refractory acute graft-versus-host disease (SR-aGvHD), contributed net revenue of US$115.2 million in its first full commercial year in the United States.

The central development: from launch to scale

Ryoncil is an allogeneic mesenchymal stromal cell therapy approved by the US Food and Drug Administration for paediatric SR-aGvHD. According to commentary on the company's earnings call, fourth-quarter revenue was about US$36 million, Gross Profit excluding Amortisation was about US$110 million for the year, and more than 50 treatment centres have been onboarded. Insurance coverage reached over 98% of US lives, and a billing code (J-code) took effect in October 2025, which can ease reimbursement.

Cash at the end of June 2026 was US$103 million. Net cash used for the year was US$43.8 million, and second-half cash burn was US$13.4 million, compared with about US$50 million in the prior-year period. Management expects FY27 cash burn to be lower than FY26 but has not said when the company will turn cash-flow positive. Mesoblast has a US$125 million Credit Facility carrying an 8% Interest Rate with no principal amortisation for five years.

Revenue drivers

Near-term revenue depends mainly on Ryoncil uptake in paediatric patients. Management expects "double-digit growth" over the next twelve months but has given no formal guidance and expects a clearer view by mid-fiscal year. Those are management expectations only. Revenue from a rare-disease therapy can be lumpy because it depends on a small number of eligible patients and treatment-centre ordering patterns.

The larger revenue question is the adult opportunity. Mesoblast estimates the adult SR-aGvHD market at about three times the paediatric market. A 180-patient randomised trial in adults with Grade 3 or 4 SR-aGvHD compares ruxolitinib alone with ruxolitinib plus Ryoncil. It is enrolling at more than 40 US sites and is expected to take about 18 months, with an interim analysis anticipated in the fourth quarter of calendar 2027 after about 100 patients. A successful interim or full result could support a supplemental Biologics licence application for adults. In compassionate use after ruxolitinib failure, 76% of patients were alive at day 100, compared with roughly 20% to 30% survival for other third-line agents cited by the company.

Pipeline beyond Ryoncil

Rexlemestrocel-L for chronic low back pain is in a Phase 3 trial with all 350 patients treated and follow-up running through twelve months. Results are expected in the second half of calendar 2027. If positive, the company plans to file a biologics licence application, with potential approval in calendar 2028. The target population is people with moderate to severe pain who have not responded to medical therapy.

The US FDA has also cleared an investigational new drug application for a paediatric Phase 3 trial of Ryoncil in Duchenne muscular dystrophy, with sites being established and no timeline provided.

Sector and competitive position

Mesoblast operates in cell and gene therapy, a field where regulatory pathways, Manufacturing consistency and payer coverage determine commercial success. In SR-aGvHD, the competing standard of care includes ruxolitinib and other agents, and Ryoncil's position as an approved paediatric option, plus the adult trial design that builds on ruxolitinib, is the company's route to expanding use.

Material risks

- Clinical risk: adult SR-aGvHD, chronic low back pain and other trials may not meet their endpoints.

- Regulatory risk: label expansions and new applications depend on FDA review outcomes.

- Commercial risk: uptake depends on treatment-centre adoption, reimbursement and physician practice.

- Financing risk: the company still burns cash and carries 8% debt, and may need additional Capital or dilution.

- Manufacturing and supply: cell therapies require consistent production and distribution.

- Timeline risk: key readouts are in 2027 or later, so near-term news may be limited to sales updates.

Reading the financial trajectory

The shift from US$17.2 million to US$120.3 million of revenue is a step change, but it is the first full commercial year, so growth rates will normalise. The better test is whether quarterly sales keep rising from the US$36 million fourth quarter without relying on initial stocking by new treatment centres.

The importance of the interim readout

The adult trial's interim analysis in the fourth quarter of calendar 2027 may be the most important near-term clinical event, because it could support a label expansion in a market the company estimates to be three times the paediatric one. Interim analyses can also be inconclusive, in which case the trial continues to full enrolment and results arrive later than hoped.

What to monitor next

The next quarterly update will show whether Ryoncil revenue continues to grow after the encouraging fourth quarter, and what happens to cash burn. Investors may also track adult trial enrolment, any interim analysis timing, the chronic low back pain readout in the second half of calendar 2027, Revascor regulatory progress and the Duchenne trial start-up.